Title
Utility of quantitative sensory testing and screening tools in identifying HIV-associated peripheral neuropathy in Western Kenya: pilot testing.

Permalink
https://escholarship.org/uc/item/9z0658f2

Journal
PloS one, 5(12)

ISSN
1932-6203

Authors
Cettomai, Deanna
Kwasa, Judith
Kendi, Caroline
et al.

Publication Date
2010-12-08

DOI
10.1371/journal.pone.0014256

Peer reviewed
Utility of Quantitative Sensory Testing and Screening Tools in Identifying HIV-Associated Peripheral Neuropathy in Western Kenya: Pilot Testing

Deanna Cettomai1,2, Judith Kwasa1, Caroline Kendi1, Gretchen L. Birbeck3, Richard W. Price2, Elizabeth A. Neuropathy in Western Kenya: Pilot Testing

Abstract

**Background/Aim:** Neuropathy is the most common neurologic complication of HIV but is widely under-diagnosed in resource-constrained settings. We aimed to identify tools that accurately distinguish individuals with moderate/severe peripheral neuropathy and can be administered by non-physician healthcare workers (HCW) in resource-constrained settings.

**Methods:** We enrolled a convenience sample of 30 HIV-infected outpatients from a Kenyan HIV-care clinic. A HCW administered the Neuropathy Severity Score (NSS), Single Question Neuropathy Screen (Single-QNS), Subjective Peripheral Neuropathy Screen (Subjective-PNS), and Brief Peripheral Neuropathy Screen (Brief-PNS). Monofilament, graduated tuning fork, and two-point discrimination examinations were performed. Tools were validated against a neurologist’s clinical assessment of moderate/severe neuropathy.

**Results:** The sample was 57% male, mean age 38.6 years, and mean CD4 count 324 cells/μL. Neurologist’s assessment identified 20% (6/30) with moderate/severe neuropathy. Diagnostic utilities for moderate/severe neuropathy were: Single-QNS - 83% sensitivity, 71% specificity; Subjective-PNS-total - 83% sensitivity, 83% specificity; Subjective-PNS-max and NSS - 67% sensitivity, 92% specificity; Brief-PNS - 0% sensitivity, 92% specificity; monofilament - 100% sensitivity, 88% specificity; graduated tuning fork - 83% sensitivity, 88% specificity; two-point discrimination - 75% sensitivity, 58% specificity.

**Conclusions:** Pilot testing suggests Single-QNS, Subjective-PNS, and monofilament examination accurately identify HIV-infected patients with moderate/severe neuropathy and may be useful diagnostic tools in resource-constrained settings.

Introduction

Peripheral neuropathy is the most common neurologic complication of HIV but is widely under-recognized and under-treated in resource-constrained settings.[1] Task-shifting, delegating healthcare tasks to less specialized healthcare workers, is common in many such locations as a result of the scale-up of antiretroviral programs.[2] Simple inexpensive diagnostic tools that can be administered by non-physician healthcare workers may improve recognition of neuropathy in resource-constrained settings.

Several screening tools and quantitative sensory testing (QST) methods, including the monofilament, Rydel-Seiffer graduated tuning fork, and two-point discriminator, have been shown to accurately identify individuals with neuropathy.[3–8] However, these tools have been almost exclusively validated in high-income countries by specialized physicians. Furthermore, none includes a functional status assessment which may be important to identify individuals with a moderate to severe neuropathy in need of intervention. Therefore, we developed the Neuropathy Severity Score (NSS), a novel diagnostic tool with a functional status assessment. We then evaluated the utility of the NSS, QST, and other previously validated diagnostic tools in identifying patients with moderate to severe peripheral neuropathy in a resource-constrained setting.

Methods

The Kenya Medical Research Institute National Ethical Review Committee and University of California San Francisco Committee on Human Research approved this study. Written informed consent was obtained from all participants. Data were analyzed using R (version 2.14.0) with a significance level of p < 0.05.
An HIV-infected outpatient over 18 years of age between September and October 2009 at Family AIDS Care and Education Services, an HIV-care clinic in Kisumu, Kenya.

Nurses and clinical officers administered the diagnostic tool under investigation (Appendix S1) to each participant. No training was provided in its administration. The tool’s components were derived from the Brief Peripheral Neuropathy Screen (Brief-PNS) [3], Subjective Peripheral Neuropathy Screen (Subjective-PNS) [4], Single Question Neuropathy Screen (Single-QNS) [5] and the physical function scale from the Medical Outcomes Study Core Study Instrument, RAND Health (www.rand.org/health/surveys_tool/mos/). Scores for Brief-PNS, Subjective-PNS, Single-QNS, and NSS (derived from Subjective-PNS and physical function scale) were obtained (Appendix S2). The nurses and clinical officers administering the tool were blinded to the neurologist’s assessment.

Study staff performed QST examination with monofilament [9,10], graduated tuning fork [7,11–13], and two-point discriminator [8] on each participant (Appendix S3). The order of QST examinations was decided using a random number table. Study staff administering QST were blinded to the neurologist’s clinical assessment in all but three cases where staffing constraints prevented blinded administration. Eighteen different nurses and clinical officers were used in the administration of the diagnostic tool; two different study staff administered QST. Intra- and inter-observer variability for QST examinations were not investigated in this study but have been previously reported.[13–15]

A neurologist performed a standardized clinical assessment based on AIDS Clinical Trials Group (ACTG) protocol.[16] The neurologist was blinded to the results of the diagnostic tool, and, in all but three cases mentioned above, blinded to the QST results. Peripheral neuropathy was defined as the presence of at least one sign of neuropathy - reduced sensation to pinprick, vibration, or reduced ankle reflexes—definitions drawn from the ACTG protocol.[16] For analysis, the study sample was dichotomized into moderate/severe and mild/no peripheral neuropathy. Moderate peripheral neuropathy was defined as pinprick diminished to the ankles or vibration reduced to 125 Hz. Sensitivity, specificity, predictive values, and accuracy were calculated. Receiver operating characteristic (ROC) curves were generated for NSS, Subjective-PNS, and two-point discrimination examinations. Kappa statistic measured agreement on tool components assessed by the neurologist and non-physician healthcare workers.

**Results**

The mean age of participants was 38.6 (±10.5 SD) years, and 17 (57%) were male. A majority of patients were WHO Stage 3 or 4, had CD4 counts <350 cells/μL, and were currently taking antiretroviral medications. Based on the neurologist’s gold standard clinical examination, 16 (53%) of participants had neuropathy with 6 (20%) individuals having moderate or severe neuropathy (Table 1). All participants with moderate/severe neuropathy had previously used stavudine (d4T), and 2 (33%) were taking d4T at study enrollment. Compared to those with mild/no neuropathy, participants with moderate/severe neuropathy had significantly lower mean household wealth and were significantly more likely to have discontinued d4T due to neuropathy.

| Age | None or Mild (n = 24) | Moderate or Severe (n = 6) | p* |
|-----|----------------------|--------------------------|----|
| Male | 37.5 (11.2) | 45 (3.8) | 0.26 |
| Household wealth (USD) | $888 (1384) | $217 (97) | 0.03 |
| Food insecurity** | 25% (6) | 0% (0) | 0.30 |
| BMI | 21.3 (2.8) | 22.3 (3.6) | 0.47 |
| CD4 nadir | 218 (158) | 114 (74) | 0.12 |
| Current d4T | 316 (229) | 353 (126) | 0.7 |
| WHO Stage 3 or 4 | 54% (13) | 83% (5) | 0.36 |
| Time since HIV diagnosis (months) | 10.4 (0.88) | 10.3 (0.52) | 0.91 |
| Ever used d4T | 67% (16) | 100% (6) | 0.16 |
| Discontinued d4T use | 46% (11) | 33% (2) | 0.67 |
| Ever used isoniazid | 42% (10) | 50% (3) | 1.0 |
| Ever used ddI | 4% (1) | 0% (0) | 1.0 |
| Any alcohol use | 17% (4) | 0% (0) | 0.56 |
| Abnormal thyroid exam | 0% (0) | 17% (1) | 0.20 |
| Mean corpuscular volume ever >100 fl | 29% (7) | 50% (3) | 0.37 |
| RRPR ever positive | 8% (2) | 0% (0) | 1.0 |
| Random blood glucose ever >200 mg/dL | 0% (0) | 0% (0) | --- |
| Fasting blood glucose ever >120 mg/dL | 0% (0) | 0% (0) | --- |
| Creatinine ever >240 μmol/L (2.7 mg/dL) | 0% (0) | 0% (0) | --- |
| ALT >80 U/L | 0% (0) | 0% (0) | --- |

Abbreviations: USD: United States Dollars; BMI: Body Mass Index; WHO: World Health Organization; d4T: stavudine; ddI: didanosine; RRPR: rapid plasma regain; ALT: alanine transaminase.

*All variables presented as [mean (SD)] or [% (n)].

*p-values calculated from two-sample t-tests of means and of Fisher’s exact tests of proportions.

**Household wealth calculated from patient self-report of household possessions.

*Food insecurity defined as eating only 1 meal per day or having gone ≥1 day without eating in the past one week.

doi:10.1371/journal.pone.0014256.t001
Table 2. Diagnostic utility of peripheral neuropathy screening tools and quantitative sensory testing in detecting moderate to severe peripheral neuropathy.

| Neuropathy Diagnostic Tool | Sensitivity [95%CI] | Specificity [95%CI] | PPV | NPV | Acc | LR+ | LR- | AUC | Cutoff |
|----------------------------|----------------------|----------------------|-----|-----|-----|-----|-----|-----|-------|
| Neuropathy Severity Score  | 66.7 [29, 104]       | 91.7 [81, 103]       | 66.7 | 91.7 | 86.7 | 8   | 0.4 | 0.83 | ≥6    |
| Subjective-PNS – Maximum Score | 66.7 [29, 104]   | 91.7 [81, 103]       | 66.7 | 91.7 | 86.7 | 8   | 0.4 | 0.83 | ≥5    |
| Subjective-PNS - Total Score | 83.3 [53, 113]     | 83.3 [68, 98]        | 55.6 | 95.2 | 83.3 | 5   | 0.2 | 0.86 | ≥6    |
| Single Question Neuropathy Screen | 83.3 [53, 113] | 70.8 [53, 89]        | 41.7 | 94.4 | 73.3 | 2.9 | 0.2 | 0.77 | ---- |
| Brief-PNS                  | 0 [0,0]              | 91.7 [81, 103]       | 0   | 78.6 | 73.3 | 0   | 1.1 | 0.46 | ---- |
| Monofilament               | 100 [100,100]       | 87.5 [74, 101]       | 66.7 | 100  | 90   | 8   | 0   | 0.94 | ≥2    |
| Graduated Tuning Fork      | 83.3 [53, 113]       | 87.5 [74, 101]       | 62.5 | 95.4 | 86.7 | 6.7 | 0.2 | 0.85 | ---- |
| Two-Point Discrimination   | 75 [40, 109]         | 58.3 [39, 78]        | 23.1 | 93.3 | 60.7 | 1.8 | 0.4 | 0.70 | ≥4    |

Abbreviations: Acc: Accuracy; PNS: Peripheral Neuropathy Screen.

Discussion

The overall prevalence of neuropathy in our sample was comparable to previously published results from similar settings.[5] While many previously established risk factors did not differ significantly between participants with moderate/severe neuropathy and those with mild/no neuropathy, mean household wealth did. Mean household wealth may be a proxy measure for another factor, such as nutritional status or the opportunity cost of accessing medical care, including missed wages or transport costs. Further investigation in a larger sample is warranted.

In our sample, NSS, Single-QNS, Subjective-PNS-total, and Subjective-PNS-max performed well and had adequate sensitivity and specificity to be useful as diagnostic tools in settings with high neuropathy prevalence. Even Single-QNS, the simplest tool, had a sensitivity over 80% and a specificity greater than 70%. A Zambian study conducted by a different research group using different methodology found Single-QNS was 96% sensitive and 80% specific.[5] These results provide support for routine use of Single-QNS in resource-constrained settings.

NSS, which was developed to incorporate functional status assessment into a diagnostic tool, did not improve gradation of neuropathy severity as we anticipated. This may be due to small sample size or insensitivity of the tool. Brief-PNS performed quite poorly in our sample, (sensitivity = 0%), which is likely the result of poor agreement of ankle reflexes between non-physician healthcare workers and the gold standard examination. Of note, we did not provide training in evaluating ankle reflexes because our goal was to identify a tool which would be feasible to scale up across sub-Saharan Africa where such training would not often be available.

Monofilament and graduated tuning fork also performed very well and may be useful in research and selected clinical settings in resource-constrained locations. QST offer objective measures of neuropathy that are less expensive, necessitate less specialized equipment, and require less training as compared to other techniques such as nerve conduction studies. In addition, some methods have been shown to predict health outcomes; for example, monofilament examination has shown significant predictive power in identifying individuals with neuropathy due to diabetes and leprosy who are at greatest risk of experiencing foot ulcerations.[6,17] However, these techniques must be validated in resource-constrained settings to ensure feasibility and accuracy.

This pilot study has several limitations. Prevalence estimates for HIV-associated neuropathy should be interpreted with caution due to small sample size, use of convenience sampling, and inclusion of only outpatients enrolled in routine care. Additionally, neuropathies identified in this population are likely due to both HIV and other etiologies, as we were unable to definitively rule out other causes. Finally, due to resource limitations, we were unable to include other objective measures of neuropathy in our gold standard, such as nerve conduction studies, computerized QST, or intra-epidermal nerve fiber densities. Nerve conduction studies can only be performed in Nairobi, Kenya, six to eight hours drive from our study site. Computerized QST technology and intra-epidermal nerve fiber densities are not currently available in Kenya. Nevertheless, a neurologist’s clinical assessment has been used widely in other studies and is an accepted gold standard.[18]

A major strength of our study is its applicability to everyday clinical practice in resource-constrained settings. Excluding QST, we did not provide specialized equipment or training to non-physician healthcare workers who administered the diagnostic tools. As such, our results are likely replicable in similar resource-constrained settings, so comparable results would be expected with widespread implementation of these tools. However, these results are preliminary and require further validation among a larger sample before generalizing more broadly to other patient populations.

Supporting Information

Appendix S1  Neuropathy Diagnostic Tool.
Found at: doi:10.1371/journal.pone.0014256.s001 (0.05 MB DOC)

Appendix S2  Scoring of individual screening tools and quantitative sensory tests.
Found at: doi:10.1371/journal.pone.0014256.s002 (0.08 MB DOC)

Appendix S3  Quantitative Sensory Testing Protocol and Normative Values.
Found at: doi:10.1371/journal.pone.0014256.s003 (0.06 MB DOC)

Acknowledgments

We would like to thank the medical officers, clinical officers, nurses, staff and patients at FACES for their participation. In addition, we would like to thank Justin McArthur, MBBS, MPH and Edwin Lwanya for their contributions to our work. This paper is published with the permission of the Director of KEMRI.
**Author Contributions**
Conceived and designed the experiments: DC JK GLB RWP EAB CRC ACM. Performed the experiments: DC JK ACM. Analyzed the data: DC ACM. Contributed reagents/materials/analysis tools: DC JK CK RWP EAB CRC. Wrote the paper: DC.

**References**

1. McArthur J, Brew B, Nath A (2005) Neurological complications of HIV. Lancet Neurol 4: 543–555.
2. World Health Organization (2006) The World Health Report - Working Together For Health; Organization WH, editor. Geneva: World Health Organization.
3. Cherry C, Wesselingh S, Lal L, McArthur J (2005) Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology 65: 1778–1781.
4. Venkataramanan AB, Skolasky RL, Creighton JA, McArthur JC (2005) Diagnostic utility of the subjective peripheral neuropathy screen in HIV-infected persons with peripheral sensory polyneuropathy. AIDS Read 15: 341–344, 348–349, 354.
5. Kandiah P, Atdolahow M, Kvalsund M, Birbeck G. Evaluating the diagnostic capacity of a single-question neuropathy screen (SQNS) in HIV positive Zambian adults. J Neurol Neurosurg Psychiatry In press.
6. Mayfield JA, Sugarman JR (2000) The use of the Semmes-Weinstein monofilament and other threshold tests for preventing foot ulceration and amputation in persons with diabetes. J Fam Pract 49: S17–29.
7. Martina IS, van Koningsveld R, Schmitz PI, van der Meche FG, van Doorn PA (1998) Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. European Inflammatory Neuropathy Cause and Treatment (INCAT) group. J Neurol Neurosurg Psychiatry 65: 743–747.
8. Periyasamy R, Manivanman M, Narayananurthy VB (2008) Changes in Two Point Discrimination and the law of mobility in Diabetes Mellitus patients. J Brachial Plex Peripher Nerve Inj 3: 3.
9. Diamond J, Mueller M, Delitto A, Sinacore D (1989) Reliability of a diabetic foot evaluation. Phys Ther 69: 797–802.
10. Arseculeratne YM, Cherry GW (2003) Sensory testing in patients with chronic venous leg ulcers using a 10 g Owen Mumford monofilament. J Wound Care 12: 215–217.
11. Kastenhauer T, Sauseng S, Brath H, Abrahamian H, Isgler K (2004) The value of the Rydel-Seiffer tuning fork as a predictor of diabetic polyneuropathy compared with a neurothesiometer. Diabet Med 21: 563–567.
12. Thivolet C, el Farh J, Petiot A, Simonet C, Tournaire J (1990) Measuring vibration sensations with graduated tuning fork. Simple and reliable means to detect diabetic patients at risk of neuropathic foot ulceration. Diabetes Care 13: 1077–1080.
13. Merkies IS, Schmitz PI, van der Meche FG, van Doorn PA (2000) Reliability and responsiveness of a graduated tuning fork in immune mediated polyneuropathies. The Inflammatory Neuropathy Cause and Treatment (INCAT) Group. J Neurol Neurosurg Psychiatry 68: 669–671.
14. Diamond JE, Mueller MJ, Delitto A, Sinacore DR (1989) Reliability of a diabetic foot evaluation. Phys Ther 69: 797–802.
15. Marx RG, Hadak PL, Bombardier C, Graham B, Goldsmith C, et al. (1998) The reliability of physical examination for carpal tunnel syndrome. J Hand Surg Br 23: 499–502.
16. Ellis RJ, Rosario D, Clifford DB, McArthur JC, Simpson D, et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol 67: 552–556.
17. Mitchell PD (2001) The threshold for protective sensation that prevents neuropathic ulceration on the planter aspect of the foot: a study of leprous patients in a rural community in India. Lepr Rev 72: 143–150.
18. McArthur J, Stocks E, Hauer P, Cornthwaith D, Griffin J (1998) Epidermal nerve fiber density: Normative reference range and diagnostic efficiency. Arch Neurol 55: 1513–1520.